Company Overview of SanBio, Inc.
SanBio, Inc. develops regenerative therapies for neurological disorders. Its product pipeline includes SB623 that reverses neural damages, as well as restores functions to damaged neurons associated with strokes, traumatic brain injuries, retinal diseases, and Parkinson's diseases; and SB618 for the treatment of neuron inflammatory injury conditions (multiple sclerosis and spinal cord injuries). The company was founded in 2001 and is based in Mountain View, California. SanBio, Inc. operates as a subsidiary of SanBio Company Limited.
231 South Whisman Road
Mountain View, CA 94041-1522
Founded in 2001
Key Executives for SanBio, Inc.
Co-Founder, Chairman and Co- Chief Executive Officer
Co-Founder, Co- Chief Executive Officer and Director
Senior Vice President of Production Development
Chief Medical Officer and Head of Research
Senior Vice President of Manufacturing
Compensation as of Fiscal Year 2016.
SanBio, Inc. Key Developments
Sanbio, Inc. Announces Randomization of First Patient in STEMTRA Phase 2 Clinical Trial Study for Traumatic Brain Injury
Jul 11 16
SanBio, Inc. announced the randomization of the first patient in the STEMTRA Phase 2 clinical trial study for traumatic brain injury. The trial is enrolling patients in both the United States and Japan, and the first patient was randomized at Emory University Hospital in Atlanta, GA. The STEMTRA “Stem cell therapy for traumatic brain injury” trial will examine the effects of SB623 stem cell treatment in patients with chronic motor deficits resulting from traumatic brain injury. SB623 cells, SanBio’s proprietary product, are modified allogeneic mesenchymal stem cells, derived from the bone marrow of healthy human adult donors. When administered into neural tissue, SB623 cells appear to promote recovery from injury by triggering the brain’s natural regenerative ability. Traumatic brain injuries can be caused by a wide range of events, including car accidents, falls, firearm mishaps, and battlefield injuries. These events often result in permanent damage, including significant motor deficits; leaving more than 5.3 million people living with disabilities in the United States alone. The STEMTRA trial follows a Phase 1/2a clinical trial in patients with chronic motor deficit secondary to ischemic stroke, which showed statistically significant improvements in motor function following implantation of the modified stem cells. The STEMTRA study will evaluate the efficacy, safety and tolerability of the SB623 cell treatment and administration process in patients with traumatic brain injuries. Patients must be at least 12 months post injury. The study will be conducted across approximately 25 clinical trial sites throughout the United States and five sites in Japan. Total enrollment is expected to reach 52 patients in total.
SanBio, Inc. Presents Interim Results of Chronic Stroke Phase 1/2a Clinical Trial at International Society of Stem Cell Research Annual Meeting
Jun 24 16
SanBio, Inc. presented the 12-month interim results of a Phase 1/2a clinical trial for the treatment of chronic motor deficits secondary to stroke at the International Society of Stem Cell Research Meeting in San Francisco. Preliminary results suggest that the company's stem cell treatment, SB623, is generally safe and well-tolerated, and may have the ability to improve motor function in patients six months to five years following an ischemic stroke. The trial was the first intracerebral stem cell transplant study for stroke in North America. It was an open-label, single-arm, dose escalation study of 18 patients with chronic motor deficits present for at least six months following an ischemic stroke. Patients received injections of SB623 cells modified allogeneic mesenchymal stem cells derived from the bone marrow of healthy human adult donors which promote recovery from injury when administered into neural tissue by triggering the brain's natural regenerative ability. The data demonstrated statistically significant improvements in motor function based on the European Stroke Scale, National Institutes of Health Stroke Scale, the Fugl-Meyer total score and the Fugl-Meyer motor function total score for all sixteen patients who completed follow-up. SanBio has followed all patients for 24 months following the procedure, and these results will be reported later this year. Based on the encouraging results of this Phase 1/2a study, SanBio and its joint development partner in North America, Sumitomo Dainippon Pharma Co. Ltd., began a Phase 2b controlled clinical trial to further investigate SB623 for the treatment of chronic motor deficits secondary to ischemic stroke. SanBio also began a Phase 2 clinical trial of SB623 for traumatic brain injury in 2015.
SanBio, Inc. Announces Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke
Jun 3 16
SanBio, Inc. announced the publication of an important paper in Stroke, a peer-reviewed journal from the American Heart Association. The paper, titled "Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study," presents the 12-month interim follow-up data from a two-year clinical trial of its SB623 stem cell treatment in patients with chronic motor deficits from ischemic stroke. These data suggest the cell treatment was both well-tolerated and effective in promoting functional recovery in those living with motor impairments six months to five years following their stroke. The trial was an open-label, single-arm dose escalation study of 18 patients. Patients had chronic motor deficits more than six months following their initial stroke. The group was split into three cohorts that each received different SB623 cell doses.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|